Enveric Biosciences Inc. (ENVB)
NASDAQ: ENVB
· Real-Time Price · USD
1.26
0.05 (4.13%)
At close: May 08, 2025, 3:59 PM
4.13% (1D)
| Bid | 1.2 |
| Market Cap | 3.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.57M |
| EPS (ttm) | -19.04 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | -0.05 |
| Analyst | Buy |
| Ask | 1.29 |
| Volume | 11,871 |
| Avg. Volume (20D) | 2,719,681 |
| Open | 1.28 |
| Previous Close | 1.21 |
| Day's Range | 1.24 - 1.28 |
| 52-Week Range | 1.01 - 222.75 |
| Beta | 0.33 |
About ENVB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENVB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+94.92%
Enveric Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago
-13.87%
Enveric Biosciences shares are trading higher after the company announced its non-hallucinogenic psychedelic compounds showed promise for treating addiction and ADHD.
2 months ago · businesswire.com
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. PatentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therap...